How I assess comorbidities before hematopoietic cell transplantation
about
Therapy-related myeloid neoplasms - what have we learned so far?Quantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events: the somatic burden score.Clinical and genetic predictors of prognosis in myelodysplastic syndromes.From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation.Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantationTreosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.Baseline body mass index among children and adults undergoing allogeneic hematopoietic cell transplantation: clinical characteristics and outcomes.Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantationEnforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research StudyMulti-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantationPre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased RelapseCombination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors.Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution.I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients.A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.Acute myeloid leukemia: 2016 Update on risk-stratification and management.Aging: Treating the Older Patient.Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host DiPretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome.Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience.Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit.Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.A retrospective review of fall risk factors in the bone marrow transplant inpatient service.Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.Allogeneic hematopoietic stem cell transplantation is associated with cure and durable remission of late-onset primary isolated central nervous system hemophagocytic lymphohistiocytosis.Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.
P2860
Q28071318-E29FB12D-6858-4DAF-8643-0BE71D796745Q33416289-8BAF12FA-432E-40BA-9047-7C82A56DFDBBQ33695906-E1B84A84-A9D2-4595-8940-A66D051A75FEQ33766984-A78F07D5-C010-4CFE-A375-481912C12BFAQ33886907-D91D16AA-0555-4E03-A00C-1101FFF525A2Q34260505-47A21B7A-0E9D-4B46-9BC8-EEF1F46F1C11Q34627218-47B4D149-A5B0-4BB3-8FE3-FC21227A8FF9Q35073850-BCAC980B-C08D-42EF-AF86-19369E541EE6Q35152208-9D9CFC70-C790-4981-9359-811A3D4D3403Q35533458-C02748ED-C471-4DF8-ADD4-A9FDB78A5326Q35583385-C18E798D-9539-45B2-AA2D-DB85060DF354Q35864056-F156ECCC-D4F4-4953-9006-4AA4327995CFQ35882830-9674D77F-4C92-47EA-932D-BF517E060381Q35920698-DCF6BB0F-81EF-4DF5-9610-595723E35005Q36543686-F9BB9040-CCD6-4152-B4E8-45B946461F37Q36608689-F3FC9B09-DBB6-4010-B3B5-C4E6ED92983AQ36821646-F4823AE5-906D-4E3E-8CE4-7169813CA26EQ37618917-87AEC264-43C7-4751-963F-C15F4A3DF3FDQ37651875-D1324D81-AB41-445A-85E5-B339209C7921Q37656904-407A4CA1-A475-4E64-B227-D9C3B43C1B83Q37657429-CA44FF87-A8DF-4E40-A77D-BEA303646A67Q38246598-3BCD152C-6A15-4DFC-B64E-F40782B8308CQ38389362-6E7D6979-CA8F-4B99-8B91-ECEC69C7E617Q38520091-A8BD77AD-0CF5-47FA-A316-3626BEE8F166Q38762572-1C3834C1-EFB0-4F49-A49A-2280A616F12FQ38858092-D9D556C8-1C59-457D-80CF-E2203F5D164AQ38897289-26C3E99C-4A9C-4C91-86E4-DE58CAC0DFF9Q39013605-B88A8F68-AE3D-47FC-A050-372404C6C363Q39601810-605F201D-5ACC-4111-B9F9-2C2C2B304DB1Q40407930-632E0B36-297A-4487-B2FD-F487C6770D14Q40414020-9E9342D3-52D6-4591-ADA1-E6EF82154BBAQ40508324-097F37F3-1DCD-469E-8B7C-5B5DAB485B93Q40551437-F1C0B214-A08D-4521-BE0E-90095D63F929Q40640735-65D6C006-2AC8-48F6-9488-0C79ED1100F2Q41896967-BCA96BE0-B71B-4956-B319-4FF620CD44FAQ41914086-CED10107-4A2A-4353-9861-209FDF575E8DQ47183946-BB79EEF9-8896-4637-9567-3116F5665760Q47648441-C79DF68B-47B7-429A-A6A0-E4F471A5222DQ48119953-0ABA4515-4D38-43F3-94BD-9EB2A75A129CQ48596388-7A6F56A2-4148-4454-83DD-A6863C2CAB85
P2860
How I assess comorbidities before hematopoietic cell transplantation
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
How I assess comorbidities before hematopoietic cell transplantation
@ast
How I assess comorbidities before hematopoietic cell transplantation
@en
type
label
How I assess comorbidities before hematopoietic cell transplantation
@ast
How I assess comorbidities before hematopoietic cell transplantation
@en
prefLabel
How I assess comorbidities before hematopoietic cell transplantation
@ast
How I assess comorbidities before hematopoietic cell transplantation
@en
P2860
P1433
P1476
How I assess comorbidities before hematopoietic cell transplantation
@en
P2093
Mohamed L Sorror
P2860
P304
P356
10.1182/BLOOD-2012-09-455063
P407
P577
2013-01-25T00:00:00Z